Extracorporeal cardiopulmonary resuscitation may improve outcomes in select patients with out-of-hospital cardiac arrest, but conflicting randomized trial data and significant logistical challenges continue to limit its broader adoption, according to a narrative review published in Minerva Medica.
Out-of-hospital cardiac arrest (OHCA) remains a major public health challenge, with survival to hospital discharge still low despite advances in emergency care. Even with bystander intervention, survival rates remain approximately 9% to 14%, underscoring the need for more effective treatment strategies.
Extracorporeal cardiopulmonary resuscitation (ECPR), which uses veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest, has gained increasing attention worldwide. Early observational studies suggested potential benefit, with reported survival to discharge as high as 29% and improved neurologic outcomes in some patients. However, randomized controlled trials have produced inconsistent results.
Three key trials highlighted in the review illustrate this variability. The ARREST trial demonstrated a significant survival benefit in a highly selected population with shockable rhythms treated at an experienced center. The Prague-OHCA trial showed a nonsignificant trend toward improved outcomes with an invasive strategy that included ECPR. In contrast, the multicenter INCEPTION trial did not demonstrate a survival advantage compared with conventional cardiopulmonary resuscitation (CPR), with outcomes potentially influenced by longer low-flow times, lower procedural success rates, and variability in center experience.
Differences in patient selection, timing, and system-level expertise likely contribute to these divergent findings. The review notes that eligibility criteria remain inconsistent across studies, although patients most likely to benefit tend to be younger, have witnessed arrests, present with shockable rhythms, and experience short no-flow and low-flow times.
Timing is a critical determinant of outcomes. ECPR is generally considered after 15 to 20 minutes of refractory cardiac arrest, and survival declines as low-flow time increases. Prolonged delays in initiating extracorporeal support are strongly associated with worse outcomes.
Implementation also presents substantial practical and ethical challenges. ECPR programs require specialized teams, advanced equipment, and significant financial investment, raising concerns about cost-effectiveness and equitable access. Complications such as bleeding and thrombosis are not uncommon. Ethical considerations include decisions about treatment withdrawal and the potential role of ECPR in preserving organ viability for donation.
The authors emphasize that optimizing patient selection, pre-cannulation care and transport, and post–cardiac arrest management are essential to achieving the best outcomes.
Ongoing clinical trials are expected to provide additional insight into patient selection, timing, and system organization, though uncertainty remains. For now, the review suggests that ECPR is most likely to achieve optimal results in experienced, high-volume centers while evidence continues to evolve.
Disclosures: The authors reported no conflicts of interest.
Source: Minerva Medica
